KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (ONC) Cash & Current Investments: 2015-2025

Historic Cash & Current Investments for BeOne Medicines (ONC) over the last 11 years, with Sep 2025 value amounting to $4.0 billion.

  • BeOne Medicines' Cash & Current Investments rose 49.41% to $4.0 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $11.9 billion, marking a year-over-year increase of 5.99%. This contributed to the annual value of $2.6 billion for FY2024, which is 17.23% down from last year.
  • Per BeOne Medicines' latest filing, its Cash & Current Investments stood at $4.0 billion for Q3 2025, which was up 46.47% from $2.8 billion recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Cash & Current Investments ranged from a high of $6.6 billion in Q4 2021 and a low of $2.5 billion during Q1 2025.
  • Moreover, its 3-year median value for Cash & Current Investments was $2.8 billion (2024), whereas its average is $3.1 billion.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first slumped by 38.63% in 2023, then surged by 49.41% in 2025.
  • BeOne Medicines' Cash & Current Investments (Quarterly) stood at $6.6 billion in 2021, then tumbled by 31.47% to $4.5 billion in 2022, then dropped by 30.00% to $3.2 billion in 2023, then fell by 17.23% to $2.6 billion in 2024, then spiked by 49.41% to $4.0 billion in 2025.
  • Its Cash & Current Investments stands at $4.0 billion for Q3 2025, versus $2.8 billion for Q2 2025 and $2.5 billion for Q1 2025.